Comprehensive Evaluation of Metabolism and the Contribution of the Hepatic First-Pass Effect in the Bioavailability of Glabridin in Rats

Glabridin is a bioactive isoflavan, which has a wide range of biological properties and is widely used in the market of health products and dietary supplements. However, the transformation pathway of glabridin in vivo is unclear, and the bioavailability is controversial among different studies. Therefore, a new HPLC-Q-TOF method was developed to analyze and identify the prototype and metabolites of glabridin in rats. A total of 63 compounds were identified, including hydroxylation, demethylation, acetylation, demethylation to carboxylation, glucuronidation, and sulfate conjugation, and 43 of which were new metabolites that had not been reported. Additionally, our study verified that the oral bioavailability of glabridin was 6.63 +/- 2.29% in rats. Furthermore, we found that the hepatic first-pass effect was 62.12 +/- 15.7% for glabridin. These results indicated that a high hepatic first-pass effect and extensive metabolism of glabridin in vivo may lead to its limited oral bioavailability.

Automated summary

A new HPLC-Q-TOF method was developed to analyze and identify the prototype and metabolites of glabridin in rats. A total of 63 compounds were identified, including 43 new metabolites. The oral bioavailability of glabridin was found to be 6.63 +/- 2.29% in rats. Additionally, the study revealed a hepatic first-pass effect of 62.12 +/- 15.7% for glabridin.